Interacting Drugs |
Methoxsalen (systemic) vs CYP2A6 Substrates |
Security Level |
 |
Mechanism |
CYP2A6 Substrates: CYP2A6 Inhibitors (Strong) may decrease the metabolism of CYP2A6 Substrates. |
Management |
Consider therapy modification |
Methoxsalen (systemic) vs CYP2A6 Substrates
Post Review about Methoxsalen (systemic) vs CYP2A6 Substrates Click here to cancel reply.
Other Interactions of Methoxsalen (systemic)
Other Interactions of CYP2A6 Substrates
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.